索玛鲁肽在≥65岁人群中的疗效和安全性：STEP试验的汇总分析.pdf

1、Busetto L et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Efficacy and safety of semaglutide in individuals aged 65 years:A pooled analysis of the STEP trialsLuca Busetto1,Niklas Kahr Rasmussen2,Naveen Rathor2,Domenica Rubino3,Lauren Wilson4,Dror Dicker5,61

2、Department of Medicine,University of Padova,Padova,Italy;2Novo Nordisk A/S,Sborg,Denmark;3Washington Center for Weight Management and Research,Arlington,VA,USA;4Novo Nordisk Inc.,Plainsboro,NJ,USA;5Internal Medicine Department D and Obesity Clinic,Hasharon Hospital-Rabin Medical Center,Petah Tikva,I

3、srael;6Gray Faculty of Medicine,Tel Aviv University,Tel Aviv,IsraelThese trials were funded by Novo Nordisk A/S and are registered with ClinicalTrials.gov(STEP 1:NCT03548935;STEP 3:NCT03611582;STEP 4:NCT03548987;STEP 5:NCT03693430;STEP 8:NCT04074161;STEP 9:NCT05064735).Medical writing support was pr

4、ovided by Ben McNeill,PhD,of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).Scan QR code or visit the web site below for:https:/ presentation portalBusetto L et al.Presented at the 33rd European Congres

5、s on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Presenter disclosure Luca Busetto reports the following:Receiving speaker fees from PronoKal and Rhythm Pharmaceuticals;and receiving consulting fees from Amgen,Boehringer Ingelheim,Bruno Farmaceutici,Eli Lilly,Novo Nordisk,Pfizer,Recordati,Regeneron a

6、nd RocheBusetto L et al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.IntroductionAE,adverse event;BMI,body mass index;GLP-1,glucagon-like peptide-1;ORC,obesity-related complication;s.c.,subcutaneous.1.Sinclair AJ and Abdelhafiz AH.Cardiovasc Endocrinol Metab